Epigenetics and MDMA-Assisted Psychotherapy for PTSD

For a detailed description of the parent study see "A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD" (ClinicalTrials.gov Identifier: NCT03537014). The current substudy the site coordinators at participating sites in the multi-site phase 3 clinical trial will collect saliva from research participants in the parent study at the following time points: 1. Collect saliva prior to first MDMA (vs placebo) treatment session at the Baseline Visit 3 or Visit 4 for the Phase 3 parent study, prior to the first MDMA (vs placebo) treatment session. 2. Collect saliva following final MDMA (vs placebo) treatment session at Primary Outcome Visit 19 or Visit 20 in the Phase 3 parent study, approximately 18 weeks after the first MDMA (vs placebo) treatment session. The collection of saliva will be accomplished using the Oragene DNA OG-500 salivary DNA kits (https://www.dnagenotek.com/ROW/products/collection-human/oragene-dna/500-series/OG-500.html). The salivary samples take no more than 2-3 minutes to collect by passive drool into the salivary collection kit.